- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04051359
Carbohydrate Restriction in Pregnant Women With Gestation Diabetes Mellitus
Effectiveness and Safety of Two Different Diets in Terms of Carbohydrate Restriction in Pregnant Women With Gestation Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Increasing prevalence of obesity and tendency to become pregnant later in life can explain rising prevalence of gestation diabetes (GDM) (1). Diabetes in pregnancy is a major public health issue: it has been shown that the mother's glycemic levels correlates perfectly with child's birth weight, death in utero, perinatal mortality and hypoglycemia (2). Therapeutic management is relatively simple and based on correction of hyperglycemia by carbohydrate restriction and energy-controlled diet adapted to pre-pregnancy BMI (3).
Although restriction of dietary carbohydrate has been the cornstone for treatment of GDM (4,5) with ACOG and The Endocrine Society recommendation for carbohydrate intake to 33-40% of total daily calories, the paucity of RCT evidence supporting safety of carbohydrate restriction still exist and actual dietary composition that optimizes perinatal outcomes is unknown (3).
Carbohydrate restriction in GDM comes with the potential increases in dietary fat intake and consequently a strong association between maternal lipids (i.e., triglycerides and free fatty acids) and excess fetal growth (6). Moreover, restrictive caloric and carbohydrate diet increases ketogenesis and ketone bodies (acetoacetate and beta-hydroxybutyrate (BHB) cross well the placental barrier.
Gestational ketogenic diet in mouse deleteriously affects the offspring growth and brain development (7), an early postnatal exposure to a ketogenic diet results in significant alterations to neonatal brain structure and can be accompanied by functional and behavioral changes in later postnatal life (8).
In the second half of pregnancy, under the influence of increasing placental hormones and cytokine concentration, lipolysis become dominant and use of free fatty acids as the energy material for the mother's body in place of glucose that is consumed mostly by the fetus.
These mechanisms are responsible for increased ketogenesis during pregnancy and are three times higher at night among pregnant women than among nonpregnant women (16). Human studies focused mostly exclusively on ketonuria; and a negative correlation between ketonuria and intellectual quotient in children born to diabetic mothers have been reported (9). Rizzo et al. did not confirm this correlation, although the authors did reveal a negative correlation between maternal β-hydroxybutyrate concentration in blood and the child's mental development (10).
On the other hand, evaluating ketone production in early pregnancy with type 1 diabetes by measuring blood BHB, the Jovanovic et al. found that despite the significantly elevated blood BHB level (2.5-fold higher than nondiabetic pregnant at 6th week gestation, and 1.6-fold at 12th week gestation), there was trend to lower BHB level in diabetic and nondiabetic mothers with malformed infants and pregnancy loss. The level of BHB was lower also in diabetic mothers of macrosomic infants (11).
Recently, inexpensive quantitative test of BHB became available using small capillary blood sample. Therefore, we would like to evaluate the levels of BHB in GDM patients treated by two different carbohydrate restricted diets in order to add an evidence on safety and proper caloric and carbohydrate restriction recommendation during pregnancy in order to optimize maternal and perinatal outcomes.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Recruiting
- Department of Endocrinology, Metabolism and Hypertension, Tel-Aviv Sourasky Medical Center
-
Contact:
- Marianna Yaron, MD
- Phone Number: +972544851224
- Email: mariannayaron@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ages 18-45 years
- GDM diagnosed between 12 and 34 weeks gestation according to Carpenter and Coustan criteria (13)
- BMI 20-35 kg/m2
- Singleton pregnancy
- Willing to perform self-monitoring of blood glucose at least 4 times a day
- Self-monitoring of blood glucose
- 12 to 34 weeks of gestation at the time of randomization
- Signed informed consent
Exclusion Criteria:
- Pre-existing diabetes in pregnancy, including first trimester fasting glucose ≥105 mg/dL
- Use of other oral hypoglycemic agents during this pregnancy
- Multiple pregnancy
- Known hepatic insufficiency (bilirubin >50 µmol/L and/or protrombin time <50 %)
- Insufficient understanding
- Participant in another investigational drug study at inclusion visits
- Fetal malformation diagnosed by previous fetal ultrasound
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Standard carbohydrate (200 g) group
Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy.
After, the randomization will be performed and GDM patients will be assigned to the standard carbohydrate (200 g) group.
|
Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (~130 grams of carbohydrates)
|
EXPERIMENTAL: Low carbohydrate (130 g) group
Assignment to treatment groups will be performed on the enrollment to the study by evaluating the dietary carbohydrate intake personal patient preferences from 3 days prospective 24 hours' food dairy.
After, the randomization will be performed and GDM patients will be assigned to the low carbohydrate (130 g) group.
|
Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (~130 grams of carbohydrates)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The rate of treatment failure defined as patients needing additional hypoglycemic therapy by long-insulin acting analogue detemir evaluated by capillary glucose levels
Time Frame: From one week after inclusion : 13 to 36 weeks of gestation to delivery
|
o The treatment failure would be defined if the fasting SMBG would be ≥95 mg/dl and/or if 1-hour post-prandial (PP) BG would be ≥140 mg/dl or 2 hour PP BG would be ≥120 mg/dl in >20% of the measurements
|
From one week after inclusion : 13 to 36 weeks of gestation to delivery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0244-18-TLV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
All women will be instructed to keep a diet of 25 kcal/kg/day for overweight and obese (pre-pregnancy BMI >25) and 35 kcal/kg for women with normal weight (pre-pregnancy BMI 18.5-24.9).
The intervention (low carbohydrate intake = RCD) group will be instructed to keep a diet divided into 3 full meals and four snacks of 130 g/d (or at least 20% of total daily caloric intake) of carbohydrate intake and high protein and high fat intake from plant-source foods (35-55% fat, and 20-25% protein). Protein content will be the same amount in both groups.
The standard carbohydrate diet (control group) group will be instructed to keep a diet divided into 3 full meals and four snacks of 200 g/d (or at least 40% of total daily caloric intake) of carbohydrate intake and high protein and high fat intake from plant-source foods (35-45% fat, and 20-25% protein).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany
Clinical Trials on Low carbohydrate (130 g) diet
-
Pennington Biomedical Research CenterCompleted
-
Uppsala UniversityCompleted
-
University of SurreyBritish Heart FoundationCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingType1diabetes, Low Carbohydrate DietUnited States
-
UCSF Benioff Children's Hospital OaklandNational Cattlemen's Beef AssociationCompletedHealthy | Cardiovascular Disease | Atherogenic DyslipidemiaUnited States
-
University of British ColumbiaMedtronicCompleted
-
University Hospital, MotolCzech Academy of SciencesRecruiting
-
Baylor UniversityCompleted
-
Haukeland University HospitalUniversity of BergenCompleted
-
Vårdcentralen LyckornaCompleted